Abstract: The present disclosure provides a bispecific antibody including a binding domain that binds to CD112R and a binding domain that binds to TIGIT, and the binding domain that binds to CD112R includes: HCDR1, HCDR2 and HCDR3 of the amino acid sequence set forth in SEQ ID NO: 1, and/or LCDR1, LCDR2 and LCDR3 of the amino acid sequence set forth in SEQ ID NO: 2; and the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined according to the Kabat, IMGT, Chothia, AbM or Contact numbering system. The present disclosure further provides a polynucleotide encoding the antibody, an expression vector, a host cell and a method for expressing and purifying the antibody, a pharmaceutical composition including the antibody of the present disclosure, and use of the bispecific antibody for treating cancer.

Abstract: Provided are a CLDN-18.2 specific binding antibody or an antigen binding fragment thereof, and a composition comprising same. Also provided are a nucleic acid molecule coding the antibody or the antigen binding fragment thereof, an expression vector and a host cell for expressing the antibody or the antigen binding fragment thereof, and a therapeutic or diagnostic method and use for the antibody or the antigen binding fragment thereof.

Abstract: An antibody specifically binding to CTLA-4 or an antigen-binding fragment thereof, and a composition comprising same. Also provided are a nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof, a vector and a host cell for expressing the antibody or an antigen-binding fragment thereof, and therapcutic and diagnostic methods and the use of the antibody or an antigen-binding fragment thereof.

Abstract: The present invention provides a stable pharmaceutical composition comprising an anti-BTLA (B and T lymphocyte attenuator) antibody and use thereof in medicines. The pharmaceutical composition comprises an anti-BTLA antibody and a buffer, further comprises at least one stabilizer, and optionally further comprises a surfactant.

Abstract: Provided are an improved uricase, a method for treating hyperuricemia using the same, and a corresponding pharmaceutical composition. The improved uricase comprises an amino acid sequence having at least about 90% identity with SEQ ID NO: 1, wherein the sequence is not SEQ ID NO: 1.

Abstract: An antibody or a functional fragment thereof that specifically bind to PD-L1 with high affinity, a nucleic acid molecule that encodes said antibody or the functional fragment thereof, an expression vector and a host cell for use in expressing said antibody or the functional fragment thereof, and a method for producing said antibody or the functional fragment thereof. An immunoconjugate and a pharmaceutical composition containing said antibody or the functional fragment thereof, and a method for using said antibody or the functional fragment thereof to enhance the function of a T cell so as to up-regulate a cell-mediated immune response, for use in treating diseases caused by T cell dysfunction.

Abstract: The present invention relates to an anti-BTLA antibody or an antigen-binding fragment thereof comprising: at least one light chain CDR domain selected from SEQ ID NOs: 7, 8, 9, 10, 11, 12, 16, 17, 18, 22, 23, 24, 31, 32 and 33, and/or at least one heavy chain CDR domain selected from SEQ ID NOs: 1, 2, 3, 4, 5, 6, 13, 14, 15, 19, 20, 21, 25, 26, 27, 28, 29 and 30. The present invention also relates to a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a corresponding expression vector and a host cell, as well as therapeutic use of the antibody or the antigen-binding fragment thereof, the nucleic acid molecule, the expression vector and the host cell.

Abstract: An antibody or a functional fragment thereof that specifically bind to PD-L1 with high affinity, a nucleic acid molecule that encodes said antibody or the functional fragment thereof, an expression vector and a host cell for use in expressing said antibody or the functional fragment thereof, and a method for producing said antibody or the functional fragment thereof. An immunoconjugate and a pharmaceutical composition containing said antibody or the functional fragment thereof, and a method for using said antibody or the functional fragment thereof to enhance the function of a T cell so as to up-regulate a cell-mediated immune response, for use in treating diseases caused by T cell dysfunction.